Answers are grounded in this paper and cite their sources.
Immunogenic cell death (ICD) is a distinct mode of regulated cell death capable of activating adaptive immune responses against tumor antigens, offering great promise for cancer immunotherapy. However, immune-excluded or “cold” tumors, characterized by poor immune infiltration and limited responsiveness to conventional immunotherapies, remain a major clinical challenge. ICD induction has emerged as a compelling strategy to convert these immunologically inert tumors into immunotherapy-sensitive, immune-active (“hot”) lesions by promoting dendritic cell activation, antigen presentation, and cytotoxic T-cell infiltration. This mini-review article highlights the potential of ICD-based therapeutic interventions, such as chemotherapy, radiotherapy, phototherapy, and nanoparticle-mediated delivery systems, to reprogram the immunosuppressive tumor microenvironment. By effectively converting cold tumors into immunologically responsive entities, ICD-centric approaches may significantly enhance the clinical efficacy of existing immunotherapies, highlighting the need for further translational research and personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: